Quick immune boost before breast cancer surgery: does it work?
NCT ID NCT05180006
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving a short course of immunotherapy (atezolizumab, alone or with other drugs) before standard treatment could increase immune cell activity in early-stage breast cancer. It involved 33 patients with triple-negative or HER2-positive breast cancer. The trial was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (with or without bevacizumab, trastuzumab, or pertuzumab)
What this could lead to
If successful, this could show that a short course of immunotherapy before standard treatment helps the immune system fight breast cancer more effectively.
What could go wrong
This was a small, early-phase trial that was terminated, so results are limited. The study focused on immune cell changes, not direct patient outcomes like survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gustave Roussy
Villejuif, 94800, France